Amalia Tejeda Velarde

Amalia Tejeda Velarde

Auto-generated profile, based on publicly available information

Amalia Tejeda Velarde

Laboratorio de HLA‐Biología Molecular, Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2021 in Science
Verified
Journal Article
Closed access
PDF file
ICIain C. Clark
Iain C. Clark
CGCristina Gutiérrez-Vázquez
Cristina Gutiérrez-Vázquez
MWMichael Wheeler
Michael Wheeler
ZLZhaorong Li
Zhaorong Li
VRVeit Rothhammer
Veit Rothhammer
FQFrancisco J. Quintana
Francisco J. Quintana
Single-cell analysis of CNS interactions: Despite their importance in the physiology and pathology of the central nervous system (CNS), few methods are available for the unbiased, systematic investigation of cell-to-cell interactions at single-cell resolution. Clark et al. developed RABID-seq, a method that combines barcoded viral tracing with single-cell RNA sequencing (see the Perspective by Silvin and Ginhoux). RABID-seq identified the axon guidance molecules Sema4D-PlexinB2 and EphrinB3-EphB3 as mediators of microglia-astrocyte interactions that promote CNS pathology in experimental autoimmune encephalomyelitis and, potentially, multiple sclerosis. These studies also identified candidate therapeutic molecules for the modulation of microglia-astrocyte interactions in multiple sclerosis. Science , this issue p. eabf1230 ; see also p. 342

1 March 2019 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
SMSusana Sainz de la Maza
Susana Sainz de la Maza
SMSilvia Medina
Silvia Medina
NVNoelia Villarrubia
Noelia Villarrubia
LCLucienne Costa-Frossard
Lucienne Costa-Frossard
EMEnric Monreal
Enric Monreal
LVLuisa M. Villar
Luisa M. Villar

15 January 2019 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
SMSilvia Medina
Silvia Medina
SMSusana Sainz de la Maza
Susana Sainz de la Maza
NVNoelia Villarrubia
Noelia Villarrubia
Roberto Álvarez-LafuenteRoberto Álvarez-Lafuente
Roberto Álvarez-Lafuente
LCLucienne Costa‐Frossard
Lucienne Costa‐Frossard
LVLuisa Maria Villar
Luisa Maria Villar
Objectives: Teriflunomide, a disease‐modifying treatment approved for multiple sclerosis (MS), inhibits reversibly dihydroorotate dehydrogenase, an enzyme involved in de novo pyrimidine biosynthesis and down‐regulates proliferation of activated lymphocytes. We aimed to study the impact of this drug in the lymphocyte profiles of MS patients.Methods: Fifty‐five patients with relapsing‐remitting MS who initiated teriflunomide treatment were included in the study. We studied peripheral blood mononuclear cells obtained before and 6 months after treatment initiation and explored effector, memory, and regulatory cells by flow cytometry. Wilcoxon matched pair tests were used to assess differences between basal and 6 months after treatment results. P‐values were corrected with Bonferroni test.Results: When explored T and B cell subsets, we observed a decrease in the percentages of terminally differentiated CD4+ T cells (P = 0.001) and plasmablasts (P < 0.0001) after 6 months of treatment. These results were confirmed with the total cell number. When studied immunomodulatory cells, we observed a clear increase of monocytes expressing programmed death‐ligand 1 (PD‐L1) (P = 0.005), which correlated negatively with all effector CD8+ T cell subsets. We also observed an increase in the percentage of CD8+ T cells (P = 0.028) and monocytes (P = 0.04) producing IL‐10.Conclusions: Teriflunomide induces a specific reduction in effector T and B cells that have shown to play a role in MS course and an increase in immunomodulatory cells. Particularly, this drug induces the expression of PD‐L1, a molecule involved in tolerance to autoantigens, which can contribute to inhibit the abnormal immune response taking place in MS.

12 April 2019 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JCJ. P. Cuello
J. P. Cuello
MGM. L. Martínez Ginés
M. L. Martínez Ginés
JKJ. Kuhle
J. Kuhle
JDJose Manuel Garcia Dominguez
Jose Manuel Garcia Dominguez
ARA. Lozano Ros
A. Lozano Ros
LVLuisa Maria Villar
Luisa Maria Villar

22 December 2017 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ATA. Tejeda‐Velarde
A. Tejeda‐Velarde
LCL. Costa‐Frossard
L. Costa‐Frossard
SMSusana Sainz de la Maza
Susana Sainz de la Maza
ÁCÁ. Carrasco
Á. Carrasco
MEM. Espiño
M. Espiño
LVLuisa Maria Villar
Luisa Maria Villar

19 February 2024 in HLA
Verified
Journal Article
Closed access
JRJairo Eduardo Niño Ramírez
Jairo Eduardo Niño Ramírez
FGFrancisco Javier Gil
Francisco Javier Gil
IHIsabel Jiménez Hernaz
Isabel Jiménez Hernaz
DADaniel Arroyo‐Sánchez
Daniel Arroyo‐Sánchez
AVAmalia Tejeda Velarde
Amalia Tejeda Velarde